首页> 中文期刊>中国卫生产业 >利妥昔单抗与CHOP方案共同应用于弥漫大B细胞性淋巴瘤治疗中的效果

利妥昔单抗与CHOP方案共同应用于弥漫大B细胞性淋巴瘤治疗中的效果

     

摘要

Objective To investigate and analyse rituximab combination with CHOP in patients with diffuse large B-cell lymphoma clinical effect. Method Select 86 cases of diffuse large B-cell lymphoma patients treatment in our hospital,randomly divided into two groups,which given rituximab with CHOP regimen combined treatment of 49 patients for the experimental group,and the remaining 37 cases only pure CHOP chemotherapy patients as the control group,the two groups of patients received six courses of treatment, the clinical effect of the two groups were compared. Results The control group efficiency was 86.49%,the experimental group efficiency of 93.88%,significantly higher than the control group(P <0.05). Conclusion Rituximab and CHOP regimen combined treatment of diffuse large B-cell lymphoma significant clinical effect,it is worth further promote in the use of clinical.%  目的探讨分析利妥昔单抗联合CHOP方案治疗弥漫大B细胞性淋巴瘤的临床效果.方法 选取该院住院治疗的弥漫大B细胞性淋巴瘤患者86例随机分成两组,其中给予利妥昔单抗与CHOP方案联合治疗的49例患者为实验组,剩下的37例仅用单纯的CHOP方案化疗的患者为对照组,两组患者在接受6个疗程的治疗后,对比两组的临床治疗效果.结果 对照组有效率为86.49%,实验组有效率达到93.88%,明显高于对照组(P<0.05).结论 利妥昔单抗与CHOP方案联合治疗弥漫大B细胞性淋巴瘤临床效果显著,值得临床上进一步推广应用.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号